BY-101298

N/A

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NameBY-101298
Drug Alias NameBY101298BY-101298AMO959AMO-959
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA-dependent protein kinase inhibitorsDNA damage response
TargetsDNA-dependent protein kinase
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-Resistant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaGermany +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChengdu Baiyu Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesChengdu Baiyu Pharma Co LtdNovartis Pharma Ag
Inactive CompaniesChengdu Baiyu Jingelai Pharmaceutical Co LtdChengdu Baiyu Pharmaceutical Co Ltd
Active IndicationsProstatic Neoplasms, Castration-Resistant
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A